The development of vaccines against cancer has driven significant advancements in tumor
immunology, leading to a better understanding of the immune response against cancer.
There is new expertise on the nature of tumor-associated antigens, making it possible to
even genetically engineer immunogenic antigens for melanoma vaccines. This has been
achieved through advances in sequencing and manipulating genomes, development of
algorithms to define putative T cell antigens, identification of different immune cell types, and …